Pathways to Ending Federal Prohibition: An Overview of Descheduling & Rescheduling. In 2022, President Biden directed his administration to conduct a review of the status of cannabis under the Controlled Substances Act. This session examines the review process for descheduling and rescheduling and their potential impacts.
Interstate Commerce in Practice: What will Interstate commerce actually look like, and how will it be regulated? Assuming interstate commerce will commence before federal legalization, this session will probe the nuances of the federal government's posture toward state-regulated interstate sales will impact how products can effectively move from state to state. Presenters will discuss the practical challenges for regulators and operators in establishing an efficient and well-regulated interstate market.
As hemp policy continues to evolve, ensure you are staying at the forefront of regulatory developments to provide your clients with the best counsel for the 2021 production season.
Learn about the licensing considerations, continuing obligations, and risk related to physical security in the cannabis industry, from mapping your business to liaising with law enforcement, and from environmental and procedural security to best practices in security employee training, join us to go through the intricacies of security in the cannabis industry.
Social Equity: Social Equity and Justice for the Indigenous Community. This CLE will focus on social equity and social justice issues within the indigenous community. Speakers will discuss tribal sovereignty, federal and state recognized tribes and barriers to entry for indigenous tribes into the cannabis industry.
In this session, hear from attorneys who are actively working on applications in the Garden State and with clients who are investing in New Jersey or otherwise gearing up for future submissions. Learn about unique-to-New Jersey license types, such as the “Conditional License,” enabling prospective operators to apply for a license without site control (subject to income restrictions), the “Micro-license,” a 2500 square foot facility for which there are no caps (subject to residency requirements), priorities in licensing, and creative opportunities to participate in the market distinct from ownership (via “Financial Source Agreement” or “Management Services Agreement”). Also learn about how the regulatory process is unfolding and how administrative delays are impacting the licensing process and accompanying operational timelines and legal transactions.
Those already in the cannabis industry and those looking to get into it will get a chance to learn more about newest adult-use markets in the country, how they compare to one another, and what we can anticipate as these new opportunities take shape.
Niall will discuss cannabis jurisdiction, legislation, regulation, Medical Cannabis Access Programme (MCAP, the Specified Controlled Drugs (Cannabis-Based Medical Products), indications, CBD - Novel Foods (Conflict of Laws), and adult use in the Republic of Ireland.
Medical Cannabis: Overview of Emerging Legal Issues and their Impact on the International Market. The international panel of experts will notably discuss the differences in regulations between medical cannabis and pharmaceutical cannabis, how IP is becoming an essential topic with pharmaceutical cannabis medicines, and how it could also impact medical cannabis in the short run.